1. Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types.
- Author
-
Wang, Feicheng, Yang, Shihao, Palmer, Nathan, Fox, Kathe, Kohane, Isaac S., Liao, Katherine P., Yu, Kun-Hsing, and Kou, S. C.
- Subjects
ADVERSE health care events ,IMMUNE checkpoint inhibitors ,CANCER treatment ,IMMUNOTHERAPY ,NIVOLUMAB ,PEMBROLIZUMAB - Abstract
Immune checkpoint inhibitors have demonstrated significant survival benefits in treating many types of cancers. However, their immune-related adverse events (irAEs) have not been systematically evaluated across cancer types in large-scale real-world populations. To address this gap, we conducted real-world data analyses using nationwide insurance claims data with 85.97 million enrollees across 8 years. We identified a significantly increased risk of developing irAEs among patients receiving immunotherapy agents in all seven cancer types commonly treated with immune checkpoint inhibitors. By six months after treatment initialization, those receiving immunotherapy were 1.50–4.00 times (95% CI, lower bound from 1.15 to 2.16, upper bound from 1.69 to 20.36) more likely to develop irAEs in the first 6 months of treatment, compared to matched chemotherapy or targeted therapy groups, with a total of 92,858 patients. The risk of developing irAEs among patients using nivolumab is higher compared to those using pembrolizumab. These results confirmed the need for clinicians to assess irAEs among cancer patients undergoing immunotherapy as part of management. Our methods are extensible to characterizing the effectiveness and adverse effects of novel treatments in large populations in an efficient and economical fashion. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF